Cellular markers based on dna damage and repair (ber, mmr), expression of mlh1, msh2, fasr, and cell death of lymphocytes as predictive parameters for clinical response to chemotherapy of melanoma

Tsitologiya

Volumn 53, Issue 1, 2011, Pages 10-16

  Tronov, V A ^a   Artamonov, D N ^b   Abramov, M E ^c   Gorbacheva, L B ^b  

^a SEMENOV INSTITUTE OF CHEMICAL PHYSICS   (Russian Federation)

^b EMANUEL INSTITUTE OF BIOCHEMICAL PHYSICS   (Russian Federation)

^c RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

Author keywords

Cell markers; Chemotherapy; DNA repair; Dna strand breaks; Lymphocytes; Melanoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD30 ANTIGEN; CISPLATIN; DACARBAZINE; LOMUSTINE; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; RECOMBINANT GAMMA INTERFERON; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ARTICLE; CELL DEATH; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MALE; MELANOMA; METABOLISM; PATHOLOGY; PROGNOSIS; SKIN TUMOR; TREATMENT OUTCOME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CISPLATIN; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LOMUSTINE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MELANOMA; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952571654     PISSN: 00413771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Al-Attar A., Gossage L., Fareed K. R., Shehata M., Mohammed M., Zaitoun A. M., Soomro I., Lobo D. N., Abbotts R., Chan S., Madhusudan S. 2010. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer. 102 : 704-709.
2. Beranek D. T. 1990. Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat. Res. 231 : 11-30. (Pubitemid 20195889)
3. Friedman H. S., Keir S., Pegg A. E., Houghton P. J., Colvin O. M., Moschel R. C., Bigner D. D., Dolan M. E. 2002. O6-benzylguanine- mediated enhancement ofchemotherapy. Mol. Cancer Ther. 1 : 943-948.
4. Gogas H. J., Kirkwood J. M., Sondak W. K. 2007. Chemotherapy for metastatic melanoma. Cancer. 109 : 455-464.
5. Hansen R. J., Nagasubramanian R., Delaney S. M., Samson L. D., Dolan M. E. 2007. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 28 : 1111-1116. (Pubitemid 47072198)
6. Hegde M. L., Karza T. K., Mitra S. 2008. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 18 : 27-47.
7. Jenkins G. J. S., Doak S. H., Johnson G. E., Quick E., Waters E. M., Parry J. M. 2005. Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis. 20 : 389-398. (Pubitemid 41816525)
8. Konca K., Lankoff A., Banasik A. et al. 2003. Across-platform public domain PC image-analysis program for comet assay. Mutat. Res. 534 : 15-20. (Pubitemid 36015835)
9. Kreklau E. L., Pollok R. T., Bailey B. J., Liu N., Hartwell J. R., Williams D. A., Erickson L. C. 2003. Hematopoietic expression of O6-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl) -1-nitrosourea. Mol. Cancer Ther. 2 : 1321-1329.
10. Liu L., Nakatsuru Y., Gerson S. L. 2002. Base excision repair as a therapeutic target in colon cancer. Clin. Cancer Res. 8 : 2985-2991. (Pubitemid 35025748)
11. Ma S., Egyhcozi S., Ringborg U., Hansson J. 2002. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Oncol. Rep. 9 : 1015-1019.
12. Middleton M. R., Lee S. M., Arance A., Wood M., Thatcher N., Margison G. P. 2000. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int. J. Cancer. 88 : 469-473.
13. Nadin S. B., Vargas-Roig L. M., Drago G., Ibarra J., Ciocca D. R. 2006. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. Cancer Lett. 239 : 84-97. (Pubitemid 43949594)
14. Naumann S. C., Roos W. P., Jost E., Belohlavek C., Lennerz V., Schmidt C. W., Christmann M., Kaina B. 2009. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br. J. Cancer. 100 : 322-333.
15. Ochs K., Kaina B. 2000. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 60 : 5815-5824.
16. Roos W. P., Batista L. F. Z., Naumann S. C., Wick W., Weller M., Menck C. F. M., Kaina B. 2007. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 26 : 186-197. (Pubitemid 46095730)
17. Roos W., Baumgartner M., Kaina B. 2004. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene. 23 : 359-367. (Pubitemid 38174989)
18. Sobol R. W., Tawbi H., Jukic D. M., Mule K., Mascari R., Kirkwood J. M. 2006. Mismatch repair (MMR) and base excision repair (BER) protein expression correlates with clinical response to dacarbazine (DTIC)/temozolomide (TMZ) therapy of patients with metastatic melanoma. J. Clin. Oncol. 24 : 8015-8016.
19. Toft N. J., Sansom O. J., Brookes R. A., Arends M. J., Wood M., Margison G. P., Winton D. J., Clarke A. R. 2000. In vivo administration of O6-benzylguanine does not influence apoptosis or mutation frequency following DNA damage in the murine intestine, but does inhibit P450-dependent activation of dacarbazine. Carcinogenesis. 21 : 593-598. (Pubitemid 30214012)
20. Watson A. J., Middleton M. R., McGown G., Thorncroft M., Ranson M., Hersey P., McArthur G., Davis I. D., Thomson D., Beith J., Haydon A., Kefford R., Lorigan P., Mortimer P., Sabharwal A., Hayward O., Margison G. P. 2009. O6-methylguanine- DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br. J. Cancer. 100 : 1250-1256.
21. Wood R. D. 1996. DNA repair in eukaryotes. Annu. Rev. Biochem. 65 : 135-167 (Pubitemid 26250607)